Carbidopa NDC 59651-146

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-146Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0146Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-146-01	59651014601	100 TABLET in 1 BOTTLE (59651-146-01)Marketed from Oct 21, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carbidopa
Generic name (nonproprietary): carbidopa
Active ingredients: Carbidopa — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211055
Marketing start: Oct 21, 2019
Listing expires: Dec 31, 2026
Identifiers: Product ID 59651-146_b5de1a51-8312-467a-9522-2e6a4046266dSPL ID b5de1a51-8312-467a-9522-2e6a4046266dSPL set ID ed98c7e1-78a6-43a5-92cd-4f085af6f09dRxCUI 260260UNII MNX7R8C5VO

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651014601 followed by a unit qualifier and the quantity

Package 59651-0146-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 29, 2021.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa tablets are for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa tablets are for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration o…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211055

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211055
Product	Strength	Form · route	Labeler	Product NDC
Carbidopa	Carbidopa 25 mg/1	TabletOral	NorthStar Rx LLC	16714-067